Navigation Links
Neurobiological Technologies, Inc. (Nasdaq: NTII) Q2/08 Review Issued By Scimitar Equity Research, Inc.
Date:2/14/2008

BOSTON, Feb. 14 /PRNewswire/ -- Scimitar Equity Research, Inc. (Scimitar) issues a review of Neurobiological Technologies, Inc. (Nasdaq: NTII), entitled, "When You Review Stroke Treatments, Look at One Stroke Drug at a Time; Each One is Different".

This review is available at our website: http://www.scimitarequity.com.

Neurobiological Technologies, Inc. (NTII) is a biotechnology company engaged in the business of acquiring and developing central nervous system related drug candidates. NTII is a specialty biopharmaceutical company with expertise in identifying and acquiring promising drug candidates and in designing and managing late-stage clinical trials for central nervous system conditions. Neurobiological Technologies, Inc is currently developing Viprinex(TM) (ancrod), a novel reperfusion agent that is in pivotal Phase 3 trials for the treatment of acute ischemic stroke. For further information, please visit NTII's website at http://www.ntii.com.

Scimitar Equity Research, Inc provides sponsored equity research of emerging healthcare companies for the investing communities. We certify that all the views expressed in this review, accurately reflect our personal views about NTII (NASDAQ) and its or their securities. No part of our compensation was, is, or will be, directly or indirectly, related to the specific recommendations or views contained in this review and we will not have any investment banking relationships or personal investment in any sponsored company. Investors are advised that this analysis and review is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy. Scimitar was paid for preparing this review. This analysis and review does not have regard to the specific investment objectives, financial situation and the information contained herein is bas
'/>"/>

SOURCE Scimitar Equity Research, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. Update: Neurobiological Technologies Sets Date for Second Quarter Financial Results and Conference Call
2. Neurobiological Technologies Sets Date for Second Quarter Financial Results
3. Neurobiological Technologies, Inc. Reports Retirement of Ronald E. Cape, Ph.D., from Board
4. Neurobiological Technologies, Inc. (Nasdaq: NTII) Q1/08 Review Issued By Scimitar Equity Research, Inc.
5. Neurobiological Technologies Announces Pricing of Its $60 Million Common Stock Offering
6. Neurobiological Technologies, Inc. (Nasdaq: NTIID)
7. Neurobiological Technologies, Inc. Reports Fourth Quarter and Fiscal Year-End Financial Results for 2007 Announces 1-for-7 Reverse Stock Split
8. Neurobiological Technologies, Inc. Reports Receipt of Notice From Nasdaq
9. Genelabs Technologies, Inc. Announces Resignation of President and CEO
10. GSA Selects Cascades Technologies, Inc. (CTi) to Support USA.gov
11. Healthcare Technologies, Ltd. Receives Notice From Nasdaq

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2009)...ILLE, Gabon, December 2 , ...Problem and Heritage" , Coinciding with t...10 the,Gabonese Republic is hosting an internation...f safeguarding biological resources in Africa. The...te leaders, ministers,scientific experts, private...
(Date:12/2/2009)...PORE, Dec. 2 S*BIO Pte Ltd today a... inhibitor, SB1518, at The American Society of Hem...Orleans. ,, Data will be presented on the clini... of SB1518 detailing its safety, tolerability and ... dose levels ranging from 100 to 600 mg. These dos...
(Date:12/2/2009)...GHAI, Dec. 2 /PRNewswire-Asia/ -- The world is goi...moil and uncertainty is part of many,businesses an...y has been,relatively immune to the economic downt..., During the midst of the difficult times thi...nson inaugurated an R&D center in Shanghai, th...
(Date:12/1/2009)...AGE, Nev., Dec. 1 PDL Bi...ed revenue guidance for the fourth quarter ended D...compared with $69 million for the fourth quarter o...s the first of two installment payments of $12.5 m...ter 2008 results was a one-time $1.8 million payme...
Breaking Biology Technology:Libreville International Conference 2-3 June 2010 2S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 2S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 3S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 4S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 5Pharma and Biotech Leaders to Converge in China at Asia Pharma R&D Leaders 2010 Summit 2Pharma and Biotech Leaders to Converge in China at Asia Pharma R&D Leaders 2010 Summit 3PDL BioPharma Provides Fourth Quarter 2009 Revenue Guidance of Approximately $57 Million 2PDL BioPharma Provides Fourth Quarter 2009 Revenue Guidance of Approximately $57 Million 3
... to create an early healthcare model should be enh...ition of Abbott Laboratories, in-vitro diagnosti...ccording to GE executives. , ,GE and Abbott annou...ement for GE, the parent GE Healthcare, to acquire... units for $8.13 billion in cash. , ,The transacti...
...Wisconsin , in response to the federal government,...a five-year, $8.1 million federal grant to develop...avian flu and the majority of potential bioterrori... National Institutes of Health,s Institute of Alle...lop a device that would be used in outpatient sett...
...elphi Group, a Boston-based consultancy focused on...Perot Systems, Innovation Lab. He will arrive in M...usion 2007 CEO-CIO Symposium . We asked him to sha... information technology professionals can work tog...ideal situation for IT working with business proce...
Other Biology Technology:GE acquisition may boost "early" healthcare strategy 2Medical College lands $8.1M grant to detect bird flu, bioterror agents 2Innovation expert speaks on the business-IT balancing act 2Innovation expert speaks on the business-IT balancing act 3Innovation expert speaks on the business-IT balancing act 4Innovation expert speaks on the business-IT balancing act 5
(Date:12/2/2009)...f, peanut butter, and other foods have done more t...safety. They also are quietly fueling a boom in th...new food safety regulations. That,s the topic of t...hemical & Engineering News , (C&EN) ACS, weekly ne...ley and Senior Correspondent Marc Reisch point out...
(Date:12/2/2009)...ring a cap is good for you, at least if you are a ...s Engineering in Oncology Center have shown that i...bers holds the cell,s nucleus, its genetic storeho... influence on cell and nuclear shape, the research...treatment of diseases such as cancer, muscular dys...
(Date:12/2/2009)...OOD SHORES, Calif. and PALM HARBOR, Fla., Dec. 2 /...e Corporation ("CIC") (OTC Bulletin Board: CICI), ...ns for business process automation in the financia...ic signature verification and Docubase Systems Inc... Document Management (EDM) software provider annou...
Breaking Biology News(10 mins):A cell's 'cap' of bundled fibers could yield clues to disease 2CIC Teams with Docubase Systems to Deliver eSignature Enabled Document Management Solutions 2CIC Teams with Docubase Systems to Deliver eSignature Enabled Document Management Solutions 3CIC Teams with Docubase Systems to Deliver eSignature Enabled Document Management Solutions 4UCR plant scientists research spawns new discoveries showing how crops survive drought 10793 1UCR plant scientists research spawns new discoveries showing how crops survive drought 10793 2UCR plant scientists research spawns new discoveries showing how crops survive drought 10793 3UCR plant scientists research spawns new discoveries showing how crops survive drought 10793 4ACCSC Grants Catherine Hinds Institute of Esthetics a Distinguished School of Excellence Award Award Recognizes High Level Achievements of Students 61638 1ACCSC Grants Catherine Hinds Institute of Esthetics a Distinguished School of Excellence Award Award Recognizes High Level Achievements of Students 61638 2ACCSC Grants Catherine Hinds Institute of Esthetics a Distinguished School of Excellence Award Award Recognizes High Level Achievements of Students 61638 3Study Shows Hospital Report Cards Unlikely to Spur Improvement 61636 1Study Shows Hospital Report Cards Unlikely to Spur Improvement 61636 2
...at a small natural history museum in the state of ...Greg Dietl chanced upon a discovery that has helpe...e shelled mollusks upon which they preyed. , In ...llion-year-old fossil from the Late Cretaceous per...ch crabs with claws of different,sizes were not kn...
...e of the nature vs. nurture debate, as North Carol...nvironmental factors such as lifestyle and geograp...turned on or off. , By studying gene expression o...rbers including desert nomads, mountain agrarians...ers and collaborators in Morocco and the United St...
... University researchers have proposed a new option...ional climate change treaty. , Kevin Gurney, lead...of the Purdue Climate Change Research Center, will... proposed deforestation and climate change policy ...Earth Day. , The approach, titled "Preservation P...
Other Biology News:Shell-breaking crabs lived 20 million years earlier than thought 2Nurture over nature 2Purdue researchers propose way to incorporate deforestation into climate change treaty 2Purdue researchers propose way to incorporate deforestation into climate change treaty 3Purdue researchers propose way to incorporate deforestation into climate change treaty 4
...ly amplify unknown genomic DNA using our patented...dy-to use components, at an extraordinarily compet...d in each kit. The BAC End Amplification kit can b...s such as P1, YAC and BAC, and localized sub-cloni...
Rabbit Anti-Human YV04 Polyclonal Antibody, Unconjugated from Atlas Antibodies
Rabbit Anti-Human YIPF6 Polyclonal Antibody, Unconjugated from Atlas Antibodies
Bovine Calf Serum - 500mL from GeneTex
Biology Products: